Reversibility of symptoms in a conditional mouse model of spinocerebellar ataxia type 3
- PMID: 19666958
- DOI: 10.1093/hmg/ddp381
Reversibility of symptoms in a conditional mouse model of spinocerebellar ataxia type 3
Abstract
Spinocerebellar ataxia type 3 (SCA3) is caused by the expansion of a CAG repeat tract that affects the MJD1 gene which encodes the ataxin-3 protein. In order to analyze whether symptoms caused by ataxin-3 with an expanded repeat are reversible in vivo, we generated a conditional mouse model of SCA3 using the Tet-Off system. We used a full-length human ataxin-3 cDNA with 77 repeats in order to generate the responder mouse line. After crossbreeding with a PrP promoter mouse line, double transgenic mice developed a progressive neurological phenotype characterized by neuronal dysfunction in the cerebellum, reduced anxiety, hyperactivity, impaired Rotarod performance and lower body weight gain. When ataxin-3 expression was turned off in symptomatic mice in an early disease state, the transgenic mice were indistinguishable from negative controls after 5 months of treatment. These results show that reducing the production of pathogenic ataxin-3 indeed may be a promising approach to treat SCA3, provided that such treatment is applied before irreversible damage has taken place and that it is continued for a sufficiently long time.
Similar articles
-
A new humanized ataxin-3 knock-in mouse model combines the genetic features, pathogenesis of neurons and glia and late disease onset of SCA3/MJD.Neurobiol Dis. 2015 Jan;73:174-88. doi: 10.1016/j.nbd.2014.09.020. Epub 2014 Oct 7. Neurobiol Dis. 2015. PMID: 25301414
-
Calpain-mediated ataxin-3 cleavage in the molecular pathogenesis of spinocerebellar ataxia type 3 (SCA3).Hum Mol Genet. 2013 Feb 1;22(3):508-18. doi: 10.1093/hmg/dds449. Epub 2012 Oct 24. Hum Mol Genet. 2013. PMID: 23100324
-
In vivo assessment of riluzole as a potential therapeutic drug for spinocerebellar ataxia type 3.J Neurochem. 2016 Jul;138(1):150-62. doi: 10.1111/jnc.13606. J Neurochem. 2016. PMID: 26990650
-
[Recent advances in molecular genetics of spinocerebellar ataxia type 3/Machado-Joseph disease].Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2008 Dec;25(6):660-2. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2008. PMID: 19065526 Review. Chinese.
-
Machado-Joseph disease/spinocerebellar ataxia type 3.Handb Clin Neurol. 2012;103:437-49. doi: 10.1016/B978-0-444-51892-7.00027-9. Handb Clin Neurol. 2012. PMID: 21827905 Free PMC article. Review.
Cited by
-
Experimental neurotransplantation treatment for hereditary cerebellar ataxias.Cerebellum Ataxias. 2016 Apr 4;3:7. doi: 10.1186/s40673-016-0045-3. eCollection 2016. Cerebellum Ataxias. 2016. PMID: 27047666 Free PMC article. Review.
-
Silencing mutant ataxin-3 rescues motor deficits and neuropathology in Machado-Joseph disease transgenic mice.PLoS One. 2013;8(1):e52396. doi: 10.1371/journal.pone.0052396. Epub 2013 Jan 22. PLoS One. 2013. PMID: 23349684 Free PMC article.
-
Is glial heme oxygenase-1 suppression in neurodegenerative disorders permissive for neural repair?Neural Regen Res. 2015 Feb;10(2):208-10. doi: 10.4103/1673-5374.152371. Neural Regen Res. 2015. PMID: 25883616 Free PMC article. No abstract available.
-
Physiological and pathophysiological characteristics of ataxin-3 isoforms.J Biol Chem. 2019 Jan 11;294(2):644-661. doi: 10.1074/jbc.RA118.005801. Epub 2018 Nov 19. J Biol Chem. 2019. PMID: 30455355 Free PMC article.
-
Removal of the Polyglutamine Repeat of Ataxin-3 by Redirecting pre-mRNA Processing.Int J Mol Sci. 2019 Oct 31;20(21):5434. doi: 10.3390/ijms20215434. Int J Mol Sci. 2019. PMID: 31683630 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials